The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-Positive HER2-Negative Non-Metastatic Breast Cancer

Background: Several studies showed the superiority of aromatase inhibitor (AI) as first-line therapy for patients with hormone-receptor (HR)-positive breast cancer (BC). For the clinician, studies in the real world are warranted to determine treatment based on the efficacy of each drug. We compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Etikasari, Ria, Andayani, Tri Murti, Endarti, Dwi, Taroeno-Hariadi, Kartika Widayati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448920/
https://www.ncbi.nlm.nih.gov/pubmed/37638281
http://dx.doi.org/10.18502/ijhoscr.v17i1.11713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448920/
https://www.ncbi.nlm.nih.gov/pubmed/37638281
http://dx.doi.org/10.18502/ijhoscr.v17i1.11713

Ejemplares similares